Orexin receptor antagonists: a review of promising compounds patented since 2006

Bibliography

• de Lecea L, Kilduff TS, Peyron C, The hypocretins: hypothalamusspecific peptides with neuroexcitatory activity. Proc Natl Acad Sci USA 1998;95:322-7
   PubMed Web of Science ®Google Scholar
• Sakurai T, Amemiya A, Ishii M, Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 1998;92:573-85
   PubMed Web of Science ®Google Scholar
• Nishino S. Clinical and neurobiological aspects of narcolepsy. Sleep Med 2007;8(4):373-399
   PubMed Web of Science ®Google Scholar
• Mochizuki T, Crocker A, McCormack S, Behavioral state instability in orexin knock-out mice. J Neurosci 2004;24(28):6291-300
   PubMed Web of Science ®Google Scholar
• Foutz AS, Mitler MM, Cavalli-Sforza LL, Dement WC. Genetic factors in canine narcolepsy. Sleep 1979;1(4):413-21
   PubMed Web of Science ®Google Scholar
• Peyron C, Faraco J, Rogers W, A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med 2000;6(9):991-7
   PubMed Web of Science ®Google Scholar
• Cai J, Cooke FE, Sherborne BS. Antagonists of the orexin receptor. Expert Opin Ther Pat 2006;16 (5):631-646
   Web of Science ®Google Scholar
• Marcus JN, Aschkenasi CJ, Lee CE, Differential expression of orexin receptors 1 and 2 in the rat brain. J Comp Neurol 2001;435(1):6-25
   PubMed Web of Science ®Google Scholar
• Ehrstrom T, Gustafsson T, Finn A, Inhibitory effect of exogenous orexin A on gastric emptying, plasma leptin, and the distribution of orexin and orexin receptors in the gut and pancreas of man. J Clin Endo Metabolism 2005;90(4):2370-2377
   PubMed Web of Science ®Google Scholar
• Zhu Y, Miwa Y, Yamanaka A, Orexin receptor type-1 couples exclusively to pertussis toxin-insensitive G-proteins, while orexin receptor type-2 couples to both pertussis toxin-sensitive and -insensitive G-proteins. J Pharmacol Sci 2003;92(3):259-66
   PubMed Web of Science ®Google Scholar
• Tang J, Chen J, Ramanjaneya M, The signalling profile of recombinant human orexin-2 receptor. Cell Signal 2008;20(9):1651-61
   PubMed Web of Science ®Google Scholar
• Lin L, Faraco J, Li R, The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 1999;98(3):365-76
   PubMed Web of Science ®Google Scholar
• Mignot E, Nishino S, Sharp LH, Heterozygosity at the canarc-1 locus can confer susceptibility for narcolepsy: induction of cataplexy in heterozygous asymptomatic dogs after administration of a combination of drugs acting on monoaminergic and cholinergic systems. J Neurosci 1993;13(3):1057-64
   PubMed Web of Science ®Google Scholar
• Riehl J, Nishino S, Cederberg R, Development of cataplexy in genetically narcoleptic Dobermans. Exp Neurol 1998;152(2):292-302
   PubMed Web of Science ®Google Scholar
• Chemelli RM, Willie JT, Sinton CM, Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 1999;98(4):437-51
   PubMed Web of Science ®Google Scholar
• Willie JT, Chemelli RM, Sinton CM, Distinct narcolepsy syndromes in Orexin receptor-2 and Orexin null mice: molecular genetic dissection of Non-REM and REM sleep regulatory processes. Neuron 2003;38(5):715-30
   PubMed Web of Science ®Google Scholar
• Scammell TE, Willie JT, Guilleminault C, Siegel JM; International Working Group on Rodent Models of Narcolepsy. A consensus definition of cataplexy in mouse models of narcolepsy. Sleep 2009;32(1):111-16
   PubMed Web of Science ®Google Scholar
• Boss C, Brisbare-Roch C, Jenck F, Orexin receptor antagonism: a new principle in neuroscience. Chimia 2008;62:974-9
   Web of Science ®Google Scholar
• Roecker AJ, Coleman PJ. Orexin receptor antagonists: medicinal chemistry and therapeutic potential. Curr Top Med Chem 2008;8(11):977-87
   PubMed Web of Science ®Google Scholar
• Boss C, Brisbare-Roch C, Jenck F. Biomedical application of orexin/hypocretin receptor ligands in neuroscience. J Med Chem 2009;52(4):891-903
   PubMed Web of Science ®Google Scholar
• Brisbare-Roch C, Dingemanse J, Koberstein R, Promotion of sleep by targeting the orexin system in rats, dogs, and humans. Nat Med 2007;13:150-5
   PubMed Web of Science ®Google Scholar
• Dugovic C, Shelton JE, Aluisio LE, Blockade of orexin-1 receptors attenuates orexin-2 receptor antagonism-induced sleep promotion in the rat. J Pharmacol Exp Ther 2009;330(1):142-51
   PubMed Web of Science ®Google Scholar
• Harris GC, Wimmer M, Aston-Jones G. A role for lateral hypothalamic orexin neurons in reward seeking. Nature 2005;437:556-9
   PubMed Web of Science ®Google Scholar
• de Lecea L, Jones BE, Boutrel B, Addiction and arousal: alternative roles of hypothalamic peptides. J Neurosci 2006;26:10372-5
   PubMed Web of Science ®Google Scholar
• Winrow CJ, Tanis KQ, Reiss DR, Orexin receptor antagonism prevents transcriptional and behavioral plasticity resulting from stimulant exposure. Neuropharmacology 2010;1:185-94
   Google Scholar
• Aston-Jones G, Smith RJ, Moorman DE, Richardson KA. Role of lateral hypothalamic orexin neurons in reward processing and addiction. Neuropharmacology 2009;56(Suppl 1):112-121
   PubMed Web of Science ®Google Scholar
• Boutrel B, Kenny PJ, Specio SE, Role for hypocretin in mediating stress-induced reinstatement of cocaine-seeking behavior. Proc Natl Acad Sci USA 2005;102(52):19168-73
   PubMed Web of Science ®Google Scholar
• Zhang GC, Mao LM, Liu XY, Wang JQ. Long-lasting up-regulation of orexin receptor type 2 protein levels in the rat nucleus accumbens after chronic cocaine administration. J Neurochem 2007;103:400-7
   PubMed Web of Science ®Google Scholar
• Dingemanse J, Dorffner G, Hajak G, Proof-of-Concept study in primary insomnia patients with almorexant (ACT-078573), a dual orexin receptor antagonist. Abstracts of Papers, World Sleep Congress; 2 – 6 September 2007, Cairns, Australia
   Google Scholar
• Actelion Pharm Ltd. WO2005118548; 2005
   Google Scholar
• Actelion Pharm Ltd. WO2007122591; 2007
   Google Scholar
• Actelion Pharm Ltd. WO2008026149; 2008
   Google Scholar
• Actelion Pharm Ltd. WO2008078291; 2008
   Google Scholar
• Actelion Pharm Ltd. WO2009004585; 2009
   Google Scholar
• Actelion Pharm Ltd. WO2009016564; 2009
   Google Scholar
• Actelion Pharm Ltd. WO2008038251; 2008
   Google Scholar
• Actelion Pharm Ltd. WO2008081399; 2008
   Google Scholar
• Actelion Pharm Ltd. WO2008065626; 2008
   Google Scholar
• Actelion Pharm Ltd. WO2008020405; 2008
   Google Scholar
• Actelion Pharm Ltd. WO2008117241; 2008
   Google Scholar
• Actelion Pharm Ltd. WO2009022311; 2009
   Google Scholar
• Smithkline Beecham Corp. WO2003051872; 2003
   Google Scholar
• Di Fabio R, Gerrard P, Porter R, Bis-amido piperidine derivatives as in vitro and in vivo potent dual orexin receptor antagonists. Abstracts of Papers, 238th ACS National Meeting; 16 – 20 August 2009, Washington, DC, United States
   Google Scholar
• Glaxo Group Ltd. WO2009034133; 2009
   Google Scholar
• Glaxo Group Ltd. WO2009003993; 2009
   Google Scholar
• Glaxo Group Ltd. WO2009003997; 2009
   Google Scholar
• Smithkline Beecham Corp. WO2003002561; 2003
   Google Scholar
• Hoffmann-La Roche, Inc. US20080249125; 2008
   Google Scholar
• Hoffmann-La Roche, Inc. WO2008107335; 2008
   Google Scholar
• Hoffmann-La Roche, Inc. WO2008110488; 2008
   Google Scholar
• Hoffmann-La Roche, Inc. WO2009016087; 2009
   Google Scholar
• Hoffmann-La Roche, Inc. US20090163485; 2009
   Google Scholar
• Merck & Co., Inc. WO2006127550; 2006
   Google Scholar
• Bergman JM, Roecker AJ, Mercer SP, Proline bis-amides as potent dual orexin antagonists. Bioorg Med Chem Lett 2008;18:1425-30
   PubMed Web of Science ®Google Scholar
• Merck & Co., Inc. WO2008008551; 2008
   Google Scholar
• Merck & Co., Inc. WO2006110626; 2006
   Google Scholar
• Merck & Co., Inc. WO2007126934; 2007
   Google Scholar
• Merck & Co., Inc. WO2007025069; 2007
   Google Scholar
• Merck & Co., Inc. WO2007126935; 2007
   Google Scholar
• Whitman DB, Cox CD, Breslin MJ, Discovery of a potent, CNS-penetrant orexin receptor antagonist based on an N,N-Disubstituted-1,4-diazepane scaffold that promotes sleep in rats. ChemMedChem 2009;4(7):1069-74
   PubMed Web of Science ®Google Scholar
• Merck & Co., Inc. WO2008008518; 2008
   Google Scholar
• Merck & Co., Inc. WO2008008517; 2008
   Google Scholar
• Merck & Co., Inc. WO2008143856; 2008
   Google Scholar
• Merck & Co., Inc. US20080132490; 2008
   Google Scholar
• Merck & Co., Inc. WO2009058238; 2009
   Google Scholar
• Merck & Co., Inc. WO2008147518; 2008
   Google Scholar
• Merck & Co., Inc. WO2008150364; 2008
   Google Scholar
• Merck & Co., Inc. WO2007061763; 2007
   Google Scholar
• Merck & Co., Inc. WO2009020642; 2009
   Google Scholar
• Merck & Co., Inc. WO2009011775; 2009
   Google Scholar
• Merck & Co., Inc. WO2007019234; 2007
   Google Scholar
• Sanofi-Aventis. WO2007085718; 2007
   Google Scholar
• Biovitrum AB. WO2006067224; 2006
   Google Scholar
• Concert Pharm, Inc. WO2009079637; 2009
   Google Scholar